{"brief_title": "Open-Label Posterior Juxtascleral Injections of Anecortave Acetate 15mg Dose for Long Term Use in Patients With AMD", "brief_summary": "The purpose of this study is to investigate the long-term efficacy and safety of posterior juxtascleral injections of open label Anecortave Acetate 15mg administered every 6 months.", "condition": ["Macular Degeneration"], "intervention_type": ["Drug"], "intervention_name": ["Anecortave Acetate (AL-3789) Sterile Suspension, 30 mg/mL"], "description": ["One 0.5 mL injection of 30 mg/mL Anecortave Acetate sterile suspension into the posterior juxtascleral depot at 6 month intervals for 18 months"], "arm_group_label": ["Anecortave Acetate, 15 mg"], "criteria": "Inclusion Criteria: - Patients with subfoveal exudative age-related macular degeneration (AMD) who were previously enrolled in long-term studies with anecortave acetate. - Other protocol-defined inclusion criteria may apply. Exclusion Criteria: - Other protocol-defined exclusion criteria may apply.", "gender": "All", "minimum_age": "50 Years", "maximum_age": "N/A", "healthy_volunteers": "No", "keyword": "Anecortave Acetate", "mesh_term": ["Macular Degeneration", "Anecortave"], "id": "NCT00065728"}